Dr Tholouli graduated in Germany and completed her haematology specialist training in Manchester where she also undertook a PhD at Manchester University investigating prognostic molecular markers in acute myeloid leukaemia. She then consolidated her transplant experience as a Transplant Fellow at the Fred Hutchinson Research Cancer Centre in Seattle, USA, one of the world’s largest stem cell transplant centres. On her return in 2007, she was appointed as a Consultant Haematologist and the Director of the Adult Stem Cell Transplant unit at Manchester Royal Infirmary. Over the years she has expanded the transplant services by pioneering alternative donor options (Umbilical cord blood and haplo-identical) and novel transplant indications (Multiple sclerosis, sickle cell disease) and set up cellular and gene therapies such as CAR-Ts, making Manchester Royal Infirmary one of the UKs largest centres.

Dr Tholouli’s expertise covers a wide range of haemato-oncological malignancies (acute and chronic leukaemia, myeloid/lymphoid leukaemia, myelodysplastic syndrome, myeloproliferative disorder, myelofibrosis, plasmacytoma, multiple myeloma, AL-amyloidosis, all types of lymphoma including Burkitt’s, post-transplant lymphoproliferative disorders and Waldenstroem’s) and non-malignant disorders (inherited/acquired bone marrow failures, aplastic anaemia, Fanconi’s, HLH, primary/secondary immunodeficiencies, mastocytosis), all aspects of stem cell transplantation and post-transplant complications including veno-occlusive disease, microangiopathy, capillary leak syndrome, idiopathic pneumonitis, neutropenic sepsis, neutropenic colitis, unusual infections of the immunocompromised host including aspergillus, candida, CMV/EBV/Adenovirus/COVID reactivations/infections, engraftment failure, graft-versus-host-disease and many others.

Dr Tholouli is the Director of the Adult Stem Cell Transplant and Cellular/Gene
Therapy Unit at Manchester Royal Infirmary and was also Director of the
Haemato-Oncology Board at Manchester Cancer from 2014 to 2022.

Dr Tholouli has a special interest in leukaemia, lymphoma, myeloma, stem cell
transplantation, and cellular & gene therapies. She is Principal Investigator for
multiple complex phase 1-4 clinical trials as well as Chief/Co-Investigator for
trials in leukaemia. She is a member of the AML working party and steering
group, directly influencing the design of trials investigating new therapies in the
UK.

Dr Tholouli has authored and co-authored many publications including original
manuscripts, review articles and book chapters, and presented at many national
and international scientific congresses. Her publications cover areas of
prognostic genes and novel therapies as well as stem cell transplant techniques
in acute myeloid leukaemia, the role of transplantation in chronic myeloid
leukaemia, management of GATA2 mutation, COVID linking to aplastic anaemia,
its effects post CAR-T therapy, outcomes of different lymphoma groups treated
with CAR-T, intensive care units and CAR-T therapy, optimising donor selection
for stem cell transplantation, outcomes of cord blood transplantation, outcomes
of haplo-identical donor transplantation, tumour lysis syndrome, treatment
options for myeloma including autologous and allogeneic stem cell transplants,
prognostic indicators in myeloma, treatment options for graft-versus-host
disease, optimal stem cell collection, management of CMV infections,
management of RSV infections, use of mesenchymal stem cells and
mastocytosis.

Dr Tholouli is a trained educational and clinical supervisor as well as appraiser.
She leads the training program on stem cell transplantation and cellular
therapies at Manchester Royal Infirmary and regularly teaches and lectures to
students at the University of Manchester.

Dr Tholouli is happy to be instructed by both Claimant and Defendant law firms in personal injury and clinical negligence matters.